LIFE SCIENCE LEGAL CONGRESS

MAY 18-19, 2027 | BOSTON

2027 Event Snapshot

The inaugural Life Science Legal Congress (LSLC 2027) will unite senior legal leaders from across the pharma, biotech and life science sector in Boston for two days of networking and strategic, interdisciplinary discussion. Geo-adapted from our established Life Science Legal Strategy Summit in Europe, the Congress will grow a strong community that brings GCs, CLOs, Heads of IP and senior in-house counsel together with leading law firms, regulators and solution providers. At its core, four GC-led keynote panels and two complementary tracks will give that community a dedicated forum to address cross-practice legal challenges facing the sector today.

200+
Senior life science legal professionals

50%
In-house counsel representation

4
GC-led keynote discussions

10+
Dedicated networking hours

Past Portfolio Speakers Include



Antje-Katrin Weigelt
SVP & General Counsel
Teva



Dorian Immler
Head of Global Intellectual Property
Bayer



Eric Whitaker
Former EVP & Chief Legal Officer
10x Genomics



Fleur Herrenschmidt
Chief Legal & Compliance Officer
Norgine



Julia Pike
Global Head of IP
Sandoz



Mark Stewart
VP, Head of Global IP Litigation
Merck



Michal Porubsky
Senior Associate General Counsel
Novo Nordisk



Petra Scamborova
Executive Director & Assistant General Counsel
Regeneron



Simon Neill
Assistant General Counsel
Johnson & Johnson



Veronika Hughes-Bednar
VP, Global Co-Head of Legal
Astellas Pharma

2027 Program Highlights

HOLISTIC KEYNOTE DISCUSSIONS

Covering core, cross-practice legal challenges, including evolving litigation landscapes, geopolitics & global market access, AI and loss-of-exclusivity

IP & EXCLUSIVITY

Biologics, combination drugs, Patent Term Extensions (PTEs), post-grant patent strategy

REGULATORY

FDA reform, clinical trials, biosimilars, MedTech, pricing & reimbursement

ANTITRUST

Monopolization, merger control, drug price-fixing, pay-for-delay & divisionals, FTC & DOJ enforcement

TRANSACTIONS

Licensing, joint ventures, collaborations, cross-border M&A, FDI screening

LITIGATION & ENFORCEMENT

Product liability, trade secrets, antitrust & M&A disputes, FDA enforcement, sanctions

Past Portfolio Attendees Include

A&O SHEARMAN	abbvie	AstraZeneca	Arnold & Porter	Baker McKenzie.	Bristol Myers Squibb
Clifford Chance	Cooley	COVINGTON	DLA PIPER	Lilly	FRESHFIELDS
GOODWIN	GSK	HOGAN LOVELLS CADWALADER	Johnson & Johnson	KIRKLAND & ELLIS	LATHAM & WATKINS LLP
Linklaters	McDermott Will & Schulte	MERCK	Morgan Lewis	NOVARTIS	Pfizer
Roche	SANDOZ	SIDLEY	teva	WILMERHALE	WHITE & CASE

Commercial Opportunities Include



PANEL SPEAKING INCLUDING 4 KEYNOTE SESSIONS



HOSTED ROUNDTABLES WITH TARGETED AUDIENCE GROUPS



1-2-1 MEETING PACKAGES WITH OUR PRECISION MATCH SERVICE FOR A CURATED APPROACH



BESPOKE BRANDING PACKAGES, INCLUDING REGISTRATION DESK, LUNCH & DRINKS